Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6670440 | 0.86 | TSHR (1.00) | TSHRSMN1; SMN2GAAPKMNPSR1 | |
| SCHEMBL17592905 | 0.86 | SMN1; SMN2 (0.76) | TSHRSMN1; SMN2GAAPKMLMNA | |
| SCHEMBL19332465 | 0.86 | GAA (0.76) | TSHRSMN1; SMN2GAAPKMLMNA | |
| SCHEMBL17593130 | 0.86 | TSHR (0.76) | TSHRSMN1; SMN2GAAPKMHTT | |
| SCHEMBL11121612 | 0.82 | TSHR (0.69) | TSHRSMN1; SMN2GAAHTTLMNA | |
| SCHEMBL17593131 | 0.82 | SMN1; SMN2 (0.69) | TSHRSMN1; SMN2HTTNPSR1LMNA | |
| SCHEMBL38666234 | 0.78 | NPSR1 (0.67) | TSHRSMN1; SMN2NPSR1LMNAALDH1A1 | |
| SCHEMBL821765 | 0.77 | TSHR (0.62) | TSHRSMN1; SMN2GAAPKMNPSR1 | |
| SCHEMBL6087035 | 0.77 | TSHR (0.63) | TSHRSMN1; SMN2GAAHTTNPSR1 | |
| Sulphamoprine SCHEMBL93846 | 0.77 | LMNA (0.67) | TSHRSMN1; SMN2NPSR1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059898-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | CANCURE LIMITED (AU) | 2011-03-10 | — | — | US | claimed |
| EP-2063884-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | Ralph, John Stephen (AU) | 2009-06-03 | — | — | EP | claimed |
| WO-2008031171-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | UNIV GRIFFITH (AU) | 2008-03-20 | — | — | WO | claimed |
| EP-2063884-B1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | RALPH STEPHEN JOHN (AU) | 2014-08-13 | — | — | EP | disclosed |
| US-8410056-B2 | Pro-oxidant anti-cancer compounds | CANCURE LIMITED (AU) | 2013-04-02 | — | — | US | disclosed |
| US-20110059898-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | CANCURE LIMITED (AU) | 2011-03-10 | — | — | US | disclosed |
| EP-2063884-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | Ralph, John Stephen (AU) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008031171-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | UNIV GRIFFITH (AU) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059898-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | PRDX5, MT-ND2, UQCRC2 | TSHR 4722/4885SMN1; SMN2 3711/4885GAA 4373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.